Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Ovarian Neoplasms

  Free Subscription

Articles published in Oncol Rep

Retrieve available abstracts of 123 articles:
HTML format

Single Articles

    August 2021
  1. WEN J, Han S, Cui M, Wang Y, et al
    [Retracted] Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

    May 2021
  2. ZHONG Y, Le F, Cheng J, Luo C, et al
    Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatinresistant SKOV3/DDP ovarian cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available

  3. LIANG X, Ju J
    Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK.
    Oncol Rep. 2021;45.
    PubMed     Abstract available

  4. LI M, Zhang S, Ma Y, Yang Y, et al
    Role of hsamiR105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
    Oncol Rep. 2021;45.
    PubMed     Abstract available

    April 2021
  5. CAO S, Chen C, Xue J, Huang Y, et al
    [Corrigendum] Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available

  6. LEE SY, Kwon J, Lee KA
    Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.
    Oncol Rep. 2021;45.
    PubMed     Abstract available

    December 2020
  7. WEI L, He Y, Bi S, Li X, et al
    miRNA199b3p suppresses growth and progression of ovarian cancer via the CHK1/Ecadherin/EMT signaling pathway by targeting ZEB1.
    Oncol Rep. 2020 Dec 11. doi: 10.3892/or.2020.7895.
    PubMed     Abstract available

  8. AN Q, Liu T, Wang MY, Yang YJ, et al
    KRT7 promotes epithelialmesenchymal transition in ovarian cancer via the TGFbeta/Smad2/3 signaling pathway.
    Oncol Rep. 2020 Dec 8. doi: 10.3892/or.2020.7886.
    PubMed     Abstract available

  9. ZHAO L, Liu Z, Deng X, Wang J, et al
    Polyphyllin VII induces mitochondrial apoptosis by regulating the PP2A/AKT/DRP1 signaling axis in human ovarian cancer.
    Oncol Rep. 2020 Dec 2. doi: 10.3892/or.2020.7879.
    PubMed     Abstract available

  10. BRUM MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al
    Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Oncol Rep. 2020 Dec 1. doi: 10.3892/or.2020.7877.
    PubMed     Abstract available

    November 2020
  11. LEE DW, Lee W, Kwon M, Lee HN, et al
    Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
    Oncol Rep. 2020 Nov 11. doi: 10.3892/or.2020.7845.
    PubMed     Abstract available

  12. ZHAO M, Ji H, Fu Q, Cheng Q, et al
    MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro.
    Oncol Rep. 2020 Nov 10. doi: 10.3892/or.2020.7844.
    PubMed     Abstract available

    October 2020
  13. ZHANG H, Hu L, Cheng M, Wang Q, et al
    The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Oncol Rep. 2020 Oct 9. doi: 10.3892/or.2020.7798.
    PubMed     Abstract available

    September 2020
  14. LIU P, Zhong Y, Cao T, Sheng X, et al
    A frequent somatic mutation in the 3'UTR of GAPDH facilitates the development of ovarian cancer by creating a miR125b binding site.
    Oncol Rep. 2020;44:887-896.
    PubMed     Abstract available

  15. ZHOU S, Wang R, Xiao H
    Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
    Oncol Rep. 2020;44:927-938.
    PubMed     Abstract available

  16. ZHANG R, Chen X, Fu S, Xu L, et al
    A small molecule STAT3 inhibitor, LLL12, enhances cisplatin and paclitaxelmediated inhibition of cell growth and migration in human ovarian cancer cells.
    Oncol Rep. 2020;44:1224-1232.
    PubMed     Abstract available

    July 2020
  17. WEN J, Han S, Cui M, Wang Y, et al
    Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2020 Jul 17. doi: 10.3892/or.2020.7694.
    PubMed     Abstract available

    May 2020
  18. PEI Y, Li K, Lou X, Wu Y, et al
    miR1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.
    Oncol Rep. 2020 May 25. doi: 10.3892/or.2020.7623.
    PubMed     Abstract available

    March 2020
  19. QIN J, Fu M, Wang J, Huang F, et al
    PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin3gallate in ovarian cancer.
    Oncol Rep. 2020 Mar 31. doi: 10.3892/or.2020.7571.
    PubMed     Abstract available

  20. WANG L, Li X
    Identification of an energy metabolismrelated gene signature in ovarian cancer prognosis.
    Oncol Rep. 2020 Mar 17. doi: 10.3892/or.2020.7548.
    PubMed     Abstract available

    February 2020
  21. SHEN JJ, Zhu XF, Xu J, Wang ZF, et al
    Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARgammadependent reversal of the progesterone receptor membrane component 1/2 expression profile.
    Oncol Rep. 2020 Feb 21. doi: 10.3892/or.2020.7509.
    PubMed     Abstract available

    December 2019
  22. LIU CL, Pan HW, Torng PL, Fan MH, et al
    SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.
    Oncol Rep. 2019;42:2706-2715.
    PubMed     Abstract available

    November 2019
  23. GAO S, Bian T, Su M, Liu Y, et al
    miR26a inhibits ovarian cancer cell proliferation, migration and invasion by targeting TCF12.
    Oncol Rep. 2019 Nov 26. doi: 10.3892/or.2019.7417.
    PubMed     Abstract available

    October 2019
  24. DONG J, Xu M
    [Corrigendum] A 19miRNA Support Vector Machine classifier and a 6miRNA risk score system designed for ovarian cancer patients.
    Oncol Rep. 2019 Oct 23. doi: 10.3892/or.2019.7385.
    PubMed     Abstract available

  25. WEI X, Jia Y, Lou H, Ma J, et al
    Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway.
    Oncol Rep. 2019 Oct 14. doi: 10.3892/or.2019.7370.
    PubMed     Abstract available

  26. SUN D, Liu J, Zhou L
    Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR646/VAMP2 and miR647/MDM2 signaling pathways.
    Oncol Rep. 2019 Oct 10. doi: 10.3892/or.2019.7366.
    PubMed     Abstract available

    September 2019
  27. ISHIKURA N, Yorozu K, Kurasawa M, Yanagisawa M, et al
    Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Oncol Rep. 2019;42:1057-1065.
    PubMed     Abstract available

    August 2019
  28. TAN WX, Xu TM, Zhou ZL, Lv XJ, et al
    TRP14 promotes resistance to cisplatin by inducing autophagy in ovarian cancer.
    Oncol Rep. 2019 Aug 2. doi: 10.3892/or.2019.7258.
    PubMed     Abstract available

  29. VACLAVIKOVA R, Klajic J, Brynychova V, Elsnerova K, et al
    Development of highresolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
    Oncol Rep. 2019;42:763-774.
    PubMed     Abstract available

    July 2019
  30. LUO H, Wang X, Ge H, Zheng N, et al
    Inhibition of ubiquitinspecific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.
    Oncol Rep. 2019 Jul 15. doi: 10.3892/or.2019.7232.
    PubMed     Abstract available

    June 2019
  31. CHEN D, Cao L, Wang X
    MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.
    Oncol Rep. 2019 Jun 12. doi: 10.3892/or.2019.7199.
    PubMed     Abstract available

    May 2019
  32. WANG Y, Yang X, Yuan M, Xian S, et al
    Promotion of ovarian cancer cell invasion, migration and colony formation by the miR21/Wnt/CD44v6 pathway.
    Oncol Rep. 2019 May 9. doi: 10.3892/or.2019.7153.
    PubMed     Abstract available

    April 2019
  33. YUAN SJ, Qiao TK, Qiang JW, Cai SQ, et al
    Dynamic contrast enhancedmagnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer.
    Oncol Rep. 2019 Apr 17. doi: 10.3892/or.2019.7124.
    PubMed     Abstract available

  34. JI M, Liu L, Hou Y, Li B, et al
    1alpha,25Dihydroxyvitamin D3 restrains stem celllike properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44.
    Oncol Rep. 2019 Apr 15. doi: 10.3892/or.2019.7116.
    PubMed     Abstract available

  35. ZHAO L, Shou H, Chen L, Gao W, et al
    Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells.
    Oncol Rep. 2019 Apr 12. doi: 10.3892/or.2019.7115.
    PubMed     Abstract available

  36. DONG J, Xu M
    A 19miRNA Support Vector Machine classifier and a 6miRNA risk score system designed for ovarian cancer patients.
    Oncol Rep. 2019 Apr 10. doi: 10.3892/or.2019.7108.
    PubMed     Abstract available

    March 2019
  37. ZHANG H, Dong R, Zhang P, Wang Y, et al
    Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl2/Bax and GSK3beta/betacatenin signaling pathways.
    Oncol Rep. 2019 Mar 15. doi: 10.3892/or.2019.7070.
    PubMed     Abstract available

  38. MALENTACCHI F, Turrini I, Sorbi F, Projetto E, et al
    Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
    Oncol Rep. 2019;41:1560-1574.
    PubMed     Abstract available

  39. KOBAYASHI H, Yamada Y, Kawahara N, Ogawa K, et al
    Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis.
    Oncol Rep. 2019;41:1729-1738.
    PubMed     Abstract available

    February 2019
  40. ZOU M, Hu X, Xu B, Tong T, et al
    Glutathione Stransferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
    Oncol Rep. 2019;41:989-998.
    PubMed     Abstract available

    January 2019
  41. WANG P, Zhang J, Xiong X, Yuan W, et al
    Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.
    Oncol Rep. 2019 Jan 28. doi: 10.3892/or.2019.6986.
    PubMed     Abstract available

  42. ALVES MR, Do Amaral NS, Marchi FA, Silva FIB, et al
    Prostaglandin D2 expression is prognostic in highgrade serous ovarian cancer.
    Oncol Rep. 2019 Jan 28. doi: 10.3892/or.2019.6984.
    PubMed     Abstract available

  43. WANG D, Xu Y, Feng L, Yin P, et al
    RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.
    Oncol Rep. 2019;41:165-177.
    PubMed     Abstract available

    December 2018
  44. WANG W, Wang J, Yan H, Zhang K, et al
    Upregulation of USP11 promotes epithelialtomesenchymal transition by deubiquitinating Snail in ovarian cancer.
    Oncol Rep. 2018 Dec 12. doi: 10.3892/or.2018.6924.
    PubMed     Abstract available

  45. LIU X, Hansen DM, Timko NJ, Zhu Z, et al
    Association between interleukin33 and ovarian cancer.
    Oncol Rep. 2018 Dec 7. doi: 10.3892/or.2018.6918.
    PubMed     Abstract available

  46. SHI J, Ye J, Fei H, Jiang SH, et al
    YWHAZ promotes ovarian cancer metastasis by modulating glycolysis.
    Oncol Rep. 2018 Dec 7. doi: 10.3892/or.2018.6920.
    PubMed     Abstract available

    November 2018
  47. MLYNSKA A, Salciuniene G, Zilionyte K, Garberyte S, et al
    Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6886.
    PubMed     Abstract available

  48. LU DH, Yang J, Gao LK, Min J, et al
    Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6888.
    PubMed     Abstract available

  49. WANG X, Han L, Zhou L, Wang L, et al
    Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network.
    Oncol Rep. 2018;40:2659-2673.
    PubMed     Abstract available

    October 2018
  50. WANG W, Du H, Liu H, Hu F, et al
    SMAD specific E3 ubiquitin protein ligase 1 promotes ovarian cancer cell migration and invasion via the activation of the RhoA/ROCK signaling pathway.
    Oncol Rep. 2018 Oct 31. doi: 10.3892/or.2018.6836.
    PubMed     Abstract available

  51. HSU CY, Hsieh TH, Er TK, Chen HS, et al
    MiR381 regulates cell motility, growth and colony formation through PIK3CA in endometriosisassociated clear cell and endometrioid ovarian cancer.
    Oncol Rep. 2018 Oct 9. doi: 10.3892/or.2018.6779.
    PubMed     Abstract available

  52. ALSAMMAN K, El-Masry OS
    Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Oncol Rep. 2018;40:2157-2162.
    PubMed     Abstract available

    September 2018
  53. GUO H, Xu Y, Wang F, Shen Z, et al
    Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
    Oncol Rep. 2018 Sep 24. doi: 10.3892/or.2018.6729.
    PubMed     Abstract available

  54. WANG YJ, Zheng LY, Wang ZF, Song R, et al
    Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.
    Oncol Rep. 2018 Sep 21. doi: 10.3892/or.2018.6725.
    PubMed     Abstract available

    August 2018
  55. XIANG J, Zhou L, Zhuang Y, Zhang J, et al
    Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSTAB1 in ovarian cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6658.
    PubMed     Abstract available

  56. LU YM, Wang Y, Liu SQ, Zhou MY, et al
    Profile and validation of dysregulated long noncoding RNAs and mRNAs in ovarian cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6654.
    PubMed     Abstract available

    July 2018
  57. SHISHIDO A, Mori S, Yokoyama Y, Hamada Y, et al
    Mesothelial cells facilitate cancer stemlike properties in spheroids of ovarian cancer cells.
    Oncol Rep. 2018 Jul 27. doi: 10.3892/or.2018.6605.
    PubMed     Abstract available

  58. MORIKAWA A, Hayashi T, Kobayashi M, Kato Y, et al
    Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
    Oncol Rep. 2018;40:309-318.
    PubMed     Abstract available

  59. KAWAI Y, Shibata K, Sakata J, Suzuki S, et al
    KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clearcell carcinoma cells.
    Oncol Rep. 2018;40:195-205.
    PubMed     Abstract available

    June 2018
  60. YANG T, Cheng J, You J, Yan B, et al
    S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
    Oncol Rep. 2018 Jun 27. doi: 10.3892/or.2018.6527.
    PubMed     Abstract available

  61. WEI Y, Han T, Wang R, Wei J, et al
    [Corrigendum] LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6495.
    PubMed     Abstract available

  62. SANCHEZ-CARRANZA JN, Diaz JF, Redondo-Horcajo M, Barasoain I, et al
    Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
    Oncol Rep. 2018;39:3007-3014.
    PubMed     Abstract available

    May 2018
  63. WEI Y, Han T, Wang R, Wei J, et al
    LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
    Oncol Rep. 2018 May 10. doi: 10.3892/or.2018.6432.
    PubMed     Abstract available

  64. WANG L, Zhang F, Cui JY, Chen L, et al
    CAFs enhance paclitaxel resistance by inducing EMT through the IL6/JAK2/STAT3 pathway.
    Oncol Rep. 2018;39:2081-2090.
    PubMed     Abstract available

    April 2018
  65. LIN Q, Guan W, Ren W, Zhang L, et al
    MALAT1 affects ovarian cancer cell behavior and patient survival.
    Oncol Rep. 2018 Apr 19. doi: 10.3892/or.2018.6384.
    PubMed     Abstract available

  66. ZHAN SJ, Liu B, Linghu H
    Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Oncol Rep. 2018 Apr 19. doi: 10.3892/or.2018.6383.
    PubMed     Abstract available

  67. GARCIA-VAZQUEZ R, Gallardo Rincon D, Ruiz-Garcia E, Meneses Garcia A, et al
    let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6366.
    PubMed     Abstract available

  68. CHEN Z, Zhu J, Zhu Y, Wang J, et al
    MicroRNA-616 promotes the progression of ovarian cancer by targeting TIMP2.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6368.
    PubMed     Abstract available

    March 2018
  69. SONG K, Lv T, Chen Y, Diao Y, et al
    Emodin inhibits TGF-beta2 by activating the FOXD3/miR199a axis in ovarian cancer cells in vitro.
    Oncol Rep. 2018 Mar 6. doi: 10.3892/or.2018.6301.
    PubMed     Abstract available

  70. XU L, Xie Q, Qi L, Wang C, et al
    Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.
    Oncol Rep. 2018;39:985-992.
    PubMed     Abstract available

    February 2018
  71. CUI Y, Wu F, Tian D, Wang T, et al
    miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Oncol Rep. 2018 Feb 12. doi: 10.3892/or.2018.6259.
    PubMed     Abstract available

  72. JANYST K, Janyst M, Siernicka M, Lasek W, et al
    Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
    Oncol Rep. 2018 Feb 6. doi: 10.3892/or.2018.6248.
    PubMed     Abstract available

  73. LIU L, Wang X, Li X, Wu X, et al
    Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
    Oncol Rep. 2018;39:818-826.
    PubMed     Abstract available

    January 2018
  74. ZHONG A, Zhang H, Xie S, Deng M, et al
    Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Oncol Rep. 2018 Jan 22. doi: 10.3892/or.2018.6229.
    PubMed     Abstract available

  75. FUJIKAKE K, Kajiyama H, Yoshihara M, Nishino K, et al
    A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer.
    Oncol Rep. 2018;39:193-200.
    PubMed     Abstract available

    December 2017
  76. HU H, Huang G, Wang H, Li X, et al
    Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6158.
    PubMed     Abstract available

  77. ZHANG N, Qiu J, Zheng T, Zhang X, et al
    Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6159.
    PubMed     Abstract available

  78. HAO Y, Zhu L, Yan L, Liu J, et al
    c-Fos mediates alpha1, 2-fucosyltransferase 1 and Lewis y expression in response to TGF-beta1 in ovarian cancer.
    Oncol Rep. 2017;38:3355-3366.
    PubMed     Abstract available

    October 2017
  79. XIE X, Yang M, Ding Y, Yu L, et al
    Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
    Oncol Rep. 2017 Oct 13. doi: 10.3892/or.2017.6034.
    PubMed     Abstract available

    September 2017
  80. SU F, Geng J, Li X, Qiao C, et al
    SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumabresistant ovarian cancer model.
    Oncol Rep. 2017 Sep 25. doi: 10.3892/or.2017.5998.
    PubMed     Abstract available

  81. GAO J, Zhu H, Wan H, Zou X, et al
    Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK/CREB pathway.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5952.
    PubMed     Abstract available

  82. PARK GB, Kim D
    TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
    Oncol Rep. 2017 Sep 6. doi: 10.3892/or.2017.5941.
    PubMed     Abstract available

    August 2017
  83. JIA L, Zhou J, Zhao H, Jin H, et al
    Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snailglycolysis pathways.
    Oncol Rep. 2017 Aug 7. doi: 10.3892/or.2017.5886.
    PubMed     Abstract available

    July 2017
  84. ZHANG J, Liu L, Han S, Li Y, et al
    B7-H3 is related to tumor progression in ovarian cancer.
    Oncol Rep. 2017 Jul 31. doi: 10.3892/or.2017.5858.
    PubMed     Abstract available

  85. BAE JS, Lee J, Park Y, Park K, et al
    Attenuation of MUC4 potentiates the anticancer activity of auranofin via regulation of the Her2/Akt/FOXO3 pathway in ovarian cancer cells.
    Oncol Rep. 2017 Jul 28. doi: 10.3892/or.2017.5853.
    PubMed     Abstract available

  86. GUO X, Guo N, Zhao J, Cai Y, et al
    Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells.
    Oncol Rep. 2017 Jul 18. doi: 10.3892/or.2017.5829.
    PubMed     Abstract available

  87. LIU N, Peng SM, Zhan GX, Yu J, et al
    Human chorionic gonadotropin beta regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.
    Oncol Rep. 2017 Jul 14. doi: 10.3892/or.2017.5818.
    PubMed     Abstract available

  88. FENG D, Zhao T, Yan K, Liang H, et al
    Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway.
    Oncol Rep. 2017 Jul 3. doi: 10.3892/or.2017.5784.
    PubMed     Abstract available

  89. QIU S, Sun L, Jin Y, An Q, et al
    Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.
    Oncol Rep. 2017;38:309-316.
    PubMed     Abstract available

    June 2017
  90. FU X, Xu L, Qi L, Tian H, et al
    BMH-21 inhibits viability and induces apoptosis by p53-dependent nucleolar stress responses in SKOV3 ovarian cancer cells.
    Oncol Rep. 2017 Jun 23. doi: 10.3892/or.2017.5750.
    PubMed     Abstract available

  91. CHEN X, Ying X, Wang X, Wu X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization.
    Oncol Rep. 2017 Jun 6. doi: 10.3892/or.2017.5697.
    PubMed     Abstract available

    May 2017
  92. CAO S, Chen C, Xue J, Huang Y, et al
    Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2017 May 25. doi: 10.3892/or.2017.5670.
    PubMed     Abstract available

  93. SHAO G, Lai W, Wan X, Xue J, et al
    Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation.
    Oncol Rep. 2017;37:2891-2896.
    PubMed     Abstract available

  94. WINKLER I, Pyszniak M, Pogoda K, Semczuk A, et al
    Assessment of Th17 lymphocytes and cytokine IL17A in epithelial ovarian tumors.
    Oncol Rep. 2017;37:3107-3115.
    PubMed     Abstract available

  95. CHO SY, Kim K, Park MS, Jang MY, et al
    Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
    Oncol Rep. 2017;37:2620-2632.
    PubMed     Abstract available

    April 2017
  96. NAKAMURA K, Terai Y, Tanabe A, Ono YJ, et al
    CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5583.
    PubMed     Abstract available

  97. LIU Y, Li H, Ban Z, Nai M, et al
    Annexin A2 inhibition suppresses ovarian cancer progression via regulating beta-catenin/EMT.
    Oncol Rep. 2017 Apr 18. doi: 10.3892/or.2017.5578.
    PubMed     Abstract available

    March 2017
  98. GAO Y, Liu X, Li T, Wei L, et al
    Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
    Oncol Rep. 2017 Mar 27. doi: 10.3892/or.2017.5534.
    PubMed     Abstract available

  99. PARK GB, Chung YH, Kim D
    Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
    Oncol Rep. 2017 Mar 27. doi: 10.3892/or.2017.5533.
    PubMed     Abstract available

  100. LIU XX, Ye H, Wang P, Li LX, et al
    Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer.
    Oncol Rep. 2017 Mar 24. doi: 10.3892/or.2017.5525.
    PubMed     Abstract available

  101. ZHANG Q, Chen WM, Zhang XX, Zhang HX, et al
    Overexpression of salusin-beta is associated with poor prognosis in ovarian cancer.
    Oncol Rep. 2017;37:1826-1832.
    PubMed     Abstract available

  102. YAN H, Qiu L, Xie X, Yang H, et al
    ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
    Oncol Rep. 2017;37:1412-1418.
    PubMed     Abstract available

  103. SATO M, Kawana K, Adachi K, Fujimoto A, et al
    Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.
    Oncol Rep. 2017;37:1883-1888.
    PubMed     Abstract available

    January 2017
  104. GU G, Chen Y, Duan C, Zhou L, et al
    Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
    Oncol Rep. 2017 Jan 18. doi: 10.3892/or.2017.5388.
    PubMed     Abstract available

  105. KIM BR, Kwon Y, Rho SB
    BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death.
    Oncol Rep. 2017;37:579-586.
    PubMed     Abstract available

    December 2016
  106. ZHANG H, Li W
    Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma.
    Oncol Rep. 2016;36:3605-3610.
    PubMed     Abstract available

    November 2016
  107. LONG Q, Yang R, Lu W, Zhu W, et al
    Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.
    Oncol Rep. 2016 Nov 21. doi: 10.3892/or.2016.5263.
    PubMed     Abstract available

  108. SHEN Y, Zhang XY, Chen X, Fan LL, et al
    Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
    Oncol Rep. 2016 Nov 18. doi: 10.3892/or.2016.5260.
    PubMed     Abstract available

    October 2016
  109. YE J, Chen W, Wu ZY, Zhang JH, et al
    Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5198.
    PubMed     Abstract available

  110. LI J, Huang H, Li Y, Li L, et al
    Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5200.
    PubMed     Abstract available

  111. SANG XB, Sun KX, Wang LL, Chen S, et al
    Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
    Oncol Rep. 2016 Oct 11. doi: 10.3892/or.2016.5164.
    PubMed     Abstract available

  112. GUO P, Xiong X, Zhang S, Peng D, et al
    miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Oncol Rep. 2016 Oct 3. doi: 10.3892/or.2016.5140.
    PubMed     Abstract available

    September 2016
  113. ZHU Q, Wu X, Wu Y, Wang X, et al
    Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5136.
    PubMed     Abstract available

  114. LU W, Lu T, Wei X
    Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5134.
    PubMed     Abstract available

  115. MENG Y, Hu J, Chen Y, Yu T, et al
    Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-kappaB and Wnt/beta-catenin pathways.
    Oncol Rep. 2016 Sep 8. doi: 10.3892/or.2016.5076.
    PubMed     Abstract available

    June 2016
  116. MA K, Wang C, Geng Q, Fan Y, et al
    Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-kappaB signaling pathways.
    Oncol Rep. 2016;35:3505-13.
    PubMed     Abstract available

    April 2016
  117. DEVOR EJ, Schickling BM, Reyes HD, Warrier A, et al
    Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
    Oncol Rep. 2016;35:2461-5.
    PubMed     Abstract available

  118. ELSNEROVA K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, et al
    Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.
    Oncol Rep. 2016;35:2159-70.
    PubMed     Abstract available

    March 2016
  119. YANG M, Xie X, Ding Y
    SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Oncol Rep. 2016;35:1796-806.
    PubMed     Abstract available

    February 2016
  120. WENG Z, Gao H, Hu J, Fan Y, et al
    Isoalantolactone induces autophagic cell death in SKOV(3) human ovarian carcinoma cells via upregulation of PEA-15.
    Oncol Rep. 2016;35:833-40.
    PubMed     Abstract available

  121. TAKEDA T, Banno K, Okawa R, Yanokura M, et al
    ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Oncol Rep. 2016;35:607-13.
    PubMed     Abstract available

  122. ZOU Y, Deng W, Wang F, Yu XH, et al
    A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
    Oncol Rep. 2016;35:725-30.
    PubMed     Abstract available

  123. KIM BR, Lee SH, Park MS, Seo SH, et al
    MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
    Oncol Rep. 2016;35:1041-8.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.